Why the study?
The authors aimed to emphasise that colchicine should be kept in mind in addition to conventional treatment in childhood myocarditis.
Does colchicine improve outcomes in childhood acute myocarditis?
Does colchicine improve outcomes in childhood acute myocarditis?
Colchicine may be a promising and cost-effective adjunctive anti-inflammatory treatment for childhood acute myocarditis.
Answers are grounded in this paper and cite their sources.
Colchicine may merit cautious consideration in refractory pediatric myocarditis; leaves open efficacy confirmation in prospective trials.
Colchicine is an FDA-approved medicine that has been used for many years to prevent and treat gout flares as well as familial mediterranean fever. It is also used off-label to treat pericarditis, calcium pyrophosphate illness, and Behçet's syndrome. There are additional studies on the use of colchicine, which is accepted as the standard treatment for pericarditis in adults, post-pericardiotomy syndrome, post-operative and post-ablation atrial fibrillation, coronary artery disorders, prior to percutaneous coronary procedures, and myocarditis. Colchicine appears to be a promising oral cardiovascular treatment targeting the inflammatory axis, owing to its low cost and moderate side-effect profile. Our aim is to emphasise that colchicine treatment, which has a strong and effective anti-inflammatory effect profile, should be kept in mind in addition to conventional treatment in childhood myocarditis.
No takes yet. Share an insight, caveat, or question.
Kavgacı et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: